Cigna earnings beat by $0.04, revenue topped estimates
Kewaunee Scientific Corporation (KEQU) stock has reached an unprecedented milestone, soaring to an all-time high of $67.82. The company, with a market capitalization of $191.26 million and an impressive "GREAT" financial health score according to InvestingPro, demonstrates solid fundamentals with a healthy current ratio of 2.64. This remarkable peak reflects a significant surge in investor confidence, as the company’s stock price has climbed steadily over the past year. The ascent to this record level marks a substantial 131.01% increase in the 1-year change data, with the company generating $199.64 million in revenue and $15.54 million in EBITDA. Trading at a P/E ratio of 10.18, InvestingPro analysis suggests the stock is currently overvalued. Investors and industry watchers alike are closely monitoring KEQU’s performance, as it continues to navigate the competitive landscape with impressive financial vigor. Discover 10 additional exclusive insights about KEQU with an InvestingPro subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.